肝细胞癌:治疗前后肿瘤生物学对不良结局及罕见治疗反应的作用
本文综述肝细胞癌(HCC)治疗后反应异质性的生物学驱动因素,强调影像预测特征虽在研究阶段但尚未验证用于临床决策,并提醒放射科医生注意治疗后肿瘤生物学改变和远隔效应等罕见反应。
要点
- HCC治疗后反应差异大,影像预测特征尚未临床验证,不能用于治疗计划。
- 阅片需警惕治疗后肿瘤生物学改变及远隔效应等罕见反应。
- 未来若验证成功,预后影像特征可用于个体化治疗。
核心结论
- HCC肿瘤生物学驱动治疗反应,影像预测特征有研究价值但尚未验证用于临床。
- 放射科医生解读治疗后HCC影像时需认识罕见反应如肿瘤生物学改变和远隔效应。
研究设计与样本
- 综述,面向常规解读HCC治疗后影像的放射科医生,旨在提高对肿瘤生物学驱动治疗反应及罕见反应的认识。
临床应用与阅片要点
- 解读HCC治疗后影像时,应结合肿瘤生物学认识反应异质性,并注意识别远隔效应等罕见反应。
- 目前影像预测特征不应用于治疗计划,需等待进一步验证。
局限性
- 综述类文章,未报告系统检索范围与纳入文献标准。
- 影像预测特征尚未在临床验证,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Liver cancer is the fastest-growing cause of cancer deaths in the United States and is a complex disease. The response of hepatocellular carcinoma (HCC) to treatment can be variable. Predicting response to determine the most effective therapy is an active area of research. Our understanding of underlying factors which drive response to therapy is continually increasing. As more therapies for the treatment of this disease evolve, it is crucial to identify and match the ideal therapy for a particular tumor and patient. The potential predicative imaging features of tumor behavior, while of research interest, have not been validated for clinical use and do not currently inform treatment planning. If further validated though, prognostic features may be used in the future to personalize treatment plans according to individual patients and tumors. Unexpected post-treatment responses such as potential tumor biology changes and abscopal effect which are important to be aware of. This review is intended for radiologists who routinely interpret post treatment HCC imaging and is designed to increase their cognizance about how HCC tumor biology drives response to therapy and explore rare responses to therapy.
引用
- Arora S, Catania R, Borhani A, et al. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdom Radiol (NY). 2021. PMID: 34195886. doi:10.1007/s00261-021-03192-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。